IMBRUVICA® – Available at Onco360
Onco360 has been selected to the extremely limited distribution network of
Specialty Pharmacies for IMBRUVICA (ibrutinib).
Refer Your IMBRUVICA Patients to Onco360
The New IMBRUVICA® pill is now available as a one-pill, once-a-day treatment. The new IMBRUVICA is the same medication, at the same dose, with the same active ingredient. For most of your patients, this will mean taking fewer pills a day.
Oncomed Dba Onco360 or
IMBRUVICA (ibrutinib) has been approved by the FDA for the four following indications and is available for prescription order through Onco360
|APPROVED INDICATIONS1||RECOMMENDED DOSAGE2|
|Chronic lymphocytic leukemia (CLL) patients||420 mg orally once daily|
|CLL patients with 17p deletion||420 mg orally once daily|
|Waldenström’s macroglobulinemia (WM) patients||420 mg orally once daily|
|Mantle cell lymphoma (MCL) patients who have received
at least one prior treatment
|560 mg orally once daily|
|Marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy||560 mg taken orally once daily|
For more information about IMBRUVICA, please visit IMBRUVICA.com.
- Imbruvica Prescribing Information
All rights in the product names, trade names, or logos of all third-party products, whether or not appearing with the registered trademark symbol, belong exclusively to their respective owners.